OTLCOTCPharmaceutical PreparationsFiscal year ends December 31

Oncotelic Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$0.02+0.00 (+11.45%)

Close on Oct 19, 2026

Market cap: $8.66M
P/E (TTM): 0.0
Dividend yield: –

Oncotelic Therapeutics, Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	TTM Q2 2025 2025-06-30	TTM Q1 2025 2025-03-31	TTM FY 2024 2024-12-31	TTM Q3 2024 2024-09-30	TTM Q2 2024 2024-06-30	TTM Q1 2024 2024-03-31	TTM FY 2023 2023-12-31	TTM Q3 2023 2023-09-30	TTM Q2 2023 2023-06-30	TTM Q1 2023 2023-03-31	TTM FY 2022 2022-12-31	TTM Q3 2022 2022-09-30	TTM Q2 2022 2022-06-30	TTM Q1 2022 2022-03-31	TTM FY 2021 2021-12-31	TTM Q3 2021 2021-09-30	TTM Q2 2021 2021-06-30	TTM Q1 2021 2021-03-31	TTM FY 2020 2020-12-31	TTM Q3 2020 2020-09-30	TTM Q2 2020 2020-06-30	TTM Q1 2020 2020-03-31	TTM FY 2019 2019-12-31	TTM Q3 2019 2019-09-30	TTM Q2 2019 2019-06-30	TTM Q1 2019 2019-03-31	TTM FY 2018 2018-12-31	TTM Q3 2018 2018-09-30	TTM Q2 2018 2018-06-30	TTM Q1 2018 2018-03-31	TTM FY 2017 2017-12-31	TTM Q3 2017 2017-09-30	TTM Q2 2017 2017-06-30	TTM Q1 2017 2017-03-31	TTM FY 2016 2016-12-31	TTM Q3 2016 2016-09-30	TTM Q2 2016 2016-06-30	TTM Q1 2016 2016-03-31	TTM FY 2015 2015-12-31	TTM Q3 2015 2015-09-30
Stock-Based Compensation	0	0	0	0	0	0	0	0.90	1.20	1.23	0.90	1.39	1.39	3.45	0.76	2.39	2.09	0	2.15	2.15	2.15	2.22	0.34	-0.12	0.08	0.16	0.08	0.73	0.73	0.78	0.84	0.82	0.82	0.85	0.80	0.91	0.86	0.91	0.81	0.59
Change in Accounts Payable	0.38	0.30	0.29	-0.23	-0.08	-0.12	-0.07	0.95	0.71	0.64	0.87	-1.10	-1.10	-0.30	0.21	1.64	1.82	1.38	0.68	0.93	0.95	0.91	0.62	0.36	0.24	0.05	0.04	0.44	0.14	0.13	0.04	-0.27	-0.19	-0.63	-0.49	-0.21	0.45	1.00	0.68	0.02
Operating Cash Flow	-0.54	-0.68	-0.74	-1.01	-1.11	-1.30	-1.32	-1.03	-0.99	-0.74	-1.45	-2.44	-3.13	-4.15	-4.43	-4.85	-5.54	-4.09	-2.81	-2.27	-1.13	-2.13	-2.28	-1.38	-1.12	0.52	-0.24	-0.99	-3.90	-8.11	-11	-14	-14	-15	-15	-14	-14	-13	-12	-12
Capital Expenditures	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-0.01	–
Purchase of Investments	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-21	–	–	–	–	–
Sale & Maturity of Investments	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	8.51	13	17	–	13	–	–	–	–	–
Investing Cash Flow	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.19	–	–	–	–	–	–	–	8.51	11	11	10	-8.51	-11	-11	–	-0.01	–
Stock Issued	–	–	–	–	–	–	–	–	–	–	0.16	0.46	0.45	–	0.42	–	–	–	–	–	–	–	0.08	0.12	0.12	–	0.24	–	–	–	–	–	–	–	–	–	–	–	9.19	9.20
Debt Repaid	–	–	–	–	–	–	–	–	–	–	–	-0.50	-0.50	-0.05	-0.10	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Financing Cash Flow	0.56	0.57	0.66	0.89	1.01	1.30	1.25	1.04	0.77	0.83	1.13	2.62	3.07	3.41	4.53	3.57	5.36	4.76	3.22	3.63	1.70	2.13	2.17	1.21	0.83	–	0.24	–	–	–	–	–	–	–	–	–	–	–	9.19	9.20
Net Change in Cash	0.02	-0.11	-0.08	-0.12	-0.11	0.00	-0.07	0.01	-0.22	0.09	-0.33	0.18	-0.06	-0.73	0.09	-1.28	-0.18	0.67	0.41	1.37	0.58	0.18	0.08	0.01	0.08	0.88	0.00	-0.79	-3.89	-5.81	-2.42	-3.26	-2.94	-4.24	-24	-25	-25	-25	-2.75	-2.64
Free Cash Flow	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-12	–
Interest Paid	0.35	0.37	0.37	0.38	0.38	0.39	0.39	0.37	0.27	0.40	0.40	0.33	0.43	0.33	0.30	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: 184.0%

Financial strength

Current ratio: 0.08
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 1.0%

Valuation

P/E ratio: 0.0
Price to sales: –
Price to book: 0.03
Dividend yield: –